DNA Repair Gene Associated with Clinical Outcome of Epithelial Ovarian Cancer Treated with Platinum-based Chemotherapy

  • Kang, Shan (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) ;
  • Sun, Hai-Yan (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) ;
  • Zhou, Rong-Miao (Department of Molecular Biology, Hebei Medical University, Fourth Hospital) ;
  • Wang, Na (Department of Molecular Biology, Hebei Medical University, Fourth Hospital) ;
  • Hu, Pei (Department of Obstetrics and Gynaecology, Hebei Medical University, Fourth Hospital) ;
  • Li, Yan (Department of Molecular Biology, Hebei Medical University, Fourth Hospital)
  • Published : 2013.02.28


Objective: The nucleotide excision repair (NER) and base excision repair (BER) pathways, two DNA repair pathways, are related to platinum resistance in cancer treatment. In this paper, we studied the association between single nucleotide polymorphisms (SNPs) of involved genes and response to platinum-based chemotherapy in epithelial ovarian cancer. Method: Eight SNPs in XRCC1 (BER), XPC and XPD (NER) were assessed in 213 patients with epithelial ovarian cancer using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and primer-introduced restriction analysis-polymerase chain reaction (PIRA-PCR) techniques. Results: The median progression-free survival (PFS) of patients carrying the Lys/Lys and Lys/Gln+Gln/Gln genotype of the XPC Lys/Gln polymorphism were 25 and 12 months, respectively (P=0.039); and the mean overall survival (OS) of patients was 31.1 and 27.8 months, respectively (P=0.048). Cox's multivariate analysis suggested that patients with epithelial ovarian cancer with the Gln allele had an increased risk of death (HR=1.75; 95% CI=1.06-2.91) compared to those with the Lys/Lys genotype. There are no associations between the XPC PAT+/-, XRCC1 Arg194Trp, Arg280His, Arg399Gln, and XPD Asp312Asn, Lys751Gln polymorphisms and the survival of patients with epithelial ovarian cancer when treated with platinum-based chemotherapy. Conclusion: Our results indicated that the XPC Lys939Gln polymorphism may correlate with clinical outcome of patients with epithelial ovarian cancer when treated with platinum-based chemotherapy in Northern China.


Supported by : natural scientific of Hebei province


  1. Azuma K, Komohara Y, Sasada T, et al (2007). Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci, 98, 1336-43.
  2. Cao ZY (2004) Chinese Obstetrics and Gynecology. Bejing Publisher, pp 2153.
  3. du Bois A, Quinn M, Thigpen T, et al (2005). 2004 consensus statements on the management of ovarian cancer, Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol, 16, viii7-12.
  4. Fleming ND, Agadjanian H, Nassanian H, et al (2012). Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer, 118, 689-97.
  5. Giachino DF, Ghio P, Regazzoni S, et al (2007). Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res, 13, 2876-81.
  6. Ji g, Lin Y, Cao SY, et al (2012). XPC939A>C and 499C>T polymorphisms and skin cancer risk, a meta-analysis. Asian Pac J Cancer Prev, 13, 4983-8.
  7. Kalikali A, Kanaki M, Vassalou H, et al (2009). DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer, 10, 118-23.
  8. Khan SG, Metter EJ, Tarone RE, et al (2000). A new xeroderma pigmentosum group C poly (AT) insertion/deletion polymorphism. Carcinogenesis, 21, 1821-5.
  9. Khan SG, Munize-Medina V, Shahlavi T, et al (2002). The human XPC DNA repair gene, arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function. Nucleic Acids Res, 30, 3624-31.
  10. Kim HS, Kim MK, Chuang HH, et al (2009). Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds, a Korean population-based study. Gynecol Oncol, 113, 264-9.
  11. Lindahl T, Wood RD (1999). Qualityc control by DNA repair. Science, 286, 1897-905.
  12. Masutani C, Sugasawa K, Yanagisawa J, et al (1994). Purification and cloning of a nucleotide excision repair complex involving the xeroderma pigmentosum group C protein and a human homologue of yeast RAD23. EMBO J, 13, 1831-43.
  13. Miller SA, Dybes DD, Polesky HF (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Re, 16, 1215.
  14. Park DJ, Stoehlmacher J, Zhang W, et al (2001). A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res, 61, 8654-58.
  15. Qiu L, Wang Z, Shi X and Wang Z (2008). Associations between XPC polymorphisms and risk of cancers, A meta-analysis. Eur J Cancer, 44, 2241-53.
  16. Reed E (1998). Platinum-DNA adduct, nucleotide excision repair and platinumbased anticancer chemotherapy. Cancer Treat Rev, 24, 331-44.
  17. Rosell R, Taron M, Barnadas A, et al (2003). Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer. Cancer Control, 10, 297-305.
  18. Saldivar JS, Lu KH, Liang D, et al (2007). Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol, 107, S223-9.
  19. Sun X, Li F, Sun N, et al (2009). Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 65, 230-6.
  20. Walsh CS, Ogawa S, Karahashi H, et al (2008). ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol, 26, 2952-8.
  21. Weaver DA, Crawford EL, Warner KA, et al (2005). ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer, 4, 18.
  22. Yu D, Zhang X, Liu J, et al (2008). Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res, 14, 2878-86.
  23. Yuan P, Miao XP, Zhang XM, et al (2005). Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer. Zhonghua Yi Xue Za Zhi, 85, 972-5.
  24. Zamble DB, Lippard SJ (1995). Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci, 20, 435-9.

Cited by

  1. Associations of ABCB1 and XPC Genetic Polymorphisms with Susceptibility to Colorectal Cancer and Therapeutic Prognosis in a Chinese Population vol.14, pp.5, 2013,
  2. Optimized Prediction of Extreme Treatment Outcomes in Ovarian Cancer vol.14s5, pp.1176-9351, 2015,
  3. gene alters the efficacy of narrowband ultraviolet B therapy in patients with active vitiligo in a Chinese population vol.173, pp.2, 2015,
  4. Single nucleotide polymorphisms (SNPs) of hOGG1 and XRCC1 DNA repair genes and the risk of ovarian cancer in Polish women vol.36, pp.12, 2015,
  5. XRCC1 polymorphism and overall survival in ovarian cancer patients treated with platinum-based chemotherapy vol.97, pp.45, 2018,